Tempus AI Past Earnings Performance
Past criteria checks 0/6
Tempus AI's earnings have been declining at an average annual rate of -26.1%, while the Life Sciences industry saw earnings growing at 3.3% annually. Revenues have been growing at an average rate of 42.9% per year.
Key information
-26.12%
Earnings growth rate
-12.27%
EPS growth rate
| Life Sciences Industry Growth | 21.51% |
| Revenue growth rate | 42.93% |
| Return on equity | -217.39% |
| Net Margin | -89.79% |
| Last Earnings Update | 31 Mar 2025 |
Recent past performance updates
Recent updates
AstraZeneca And Pathos Partnership Will Expand Precision Medicine
Pharma partnerships and the shift toward AI-driven precision medicine are fueling strong, high-margin revenue growth and expanding Tempus' competitive opportunities.I'm Still Bullish On Tempus AI
Jun 07The Tempus AI, Inc. (NASDAQ:TEM) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 09
Tempus: The AI Engine Powering Healthcare
Apr 20Is Tempus AI (NASDAQ:TEM) A Risky Investment?
Mar 25Tempus AI's Valuation Bakes In Strong Growth - A Hold For Now
Mar 25Tempus AI: The Investment Opportunity Of A Decade, Strong Buy
Mar 18Earnings Update: Here's Why Analysts Just Lifted Their Tempus AI, Inc. (NASDAQ:TEM) Price Target To US$64.11
Feb 27Tempus AI Earnings: A Promising Business, But There Are Risks
Feb 25Tempus AI Is A Buy On Dips In The AI-Driven Healthcare Sector
Feb 18Why Investors Shouldn't Be Surprised By Tempus AI, Inc.'s (NASDAQ:TEM) 82% Share Price Surge
Feb 11Tempus AI: In Vogue, But Better To Wait For Some Retracement
Feb 05Tempus AI: Don't Be Blindly Optimistic On Anything AI
Jan 28Tempus AI: Why I'm Avoiding This Stock In 2025
Jan 21The Price Is Right For Tempus AI, Inc (NASDAQ:TEM) Even After Diving 26%
Dec 18Tempus AI: Recent Weakness Presents Gift Ahead Of The Holidays
Dec 18Tempus AI: Why I'm Buying This AI Stock
Dec 08Tempus AI: Pioneering The Future Of Precision Medicine Through AI-Driven Innovation
Nov 12Tempus: Attempting To Lead The AI Revolution In Healthcare
Oct 29Tempus AI: Deploying AI In Precision Medicine; Initiate With 'Buy'
Aug 21Tempus AI: Healthcare AI Play Faces Some Challenges From The Start
Jun 14Revenue & Expenses Breakdown
How Tempus AI makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 25 | 803 | -721 | 831 | 335 |
| 31 Dec 24 | 693 | -746 | 755 | 317 |
| 30 Sep 24 | 640 | -801 | 729 | 304 |
| 30 Jun 24 | 596 | -790 | 700 | 293 |
| 31 Mar 24 | 562 | -293 | 308 | 193 |
| 31 Dec 23 | 532 | -266 | 297 | 178 |
| 30 Sep 23 | 485 | -276 | 276 | 172 |
| 31 Dec 22 | 321 | -334 | 237 | 162 |
| 30 Sep 22 | 293 | -325 | 222 | 156 |
| 31 Dec 21 | 258 | -298 | 194 | 128 |
| 30 Sep 21 | 285 | -296 | 180 | 118 |
| 30 Jun 21 | 284 | -286 | 161 | 110 |
| 31 Mar 21 | 236 | -270 | 142 | 101 |
| 31 Dec 20 | 188 | -254 | 124 | 91 |
| 31 Dec 19 | 62 | -148 | 79 | 57 |
Quality Earnings: TEM is currently unprofitable.
Growing Profit Margin: TEM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TEM is unprofitable, and losses have increased over the past 5 years at a rate of 26.1% per year.
Accelerating Growth: Unable to compare TEM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TEM is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-6.1%).
Return on Equity
High ROE: TEM has a negative Return on Equity (-217.39%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/16 13:44 |
| End of Day Share Price | 2025/06/13 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tempus AI, Inc. is covered by 13 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Ryskin | BofA Global Research |
| Mark Massaro | BTIG |
| Subhalaxmi Nambi | Guggenheim Securities, LLC |